Biotech

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company") is pleased to announce that it has secured the Presenting Level Sponsorship position at the Planted Expo at the Vancouver Convention Centre West from November 20th-21st. More information can be found at www.PlantedLife.comVancouver.

The Planted Expo (formerly Veg Expo) is a popular consumer event and billed as Canada's largest plant-based event of the year. The event houses over 200 vegan edible and lifestyle businesses in one location. All Boosh shareholders attending the show will receive a free swag bag including coupons for Boosh products as well as Boosh apparel.

"This is such an outstanding opportunity for Team Boosh to meet thousands of consumers looking to incorporate more plant-based foods into their diet. Our 2,000 sq ft booth is located in front of the stage and designed to be family oriented with games for the kids, lots of taste testing, guest chefs cooking up delicious treats, and our entire line of Boosh frozen and refrigerated meals available for purchase on the spot!" states founder Connie Marples.

"We look forward to seeing all of our shareholders, their family and friends in person, enjoying our Boosh products while receiving company updates and meeting the team," states CEO Jim Pakulis.

In other news, the Company announces that it has received approval to trade on the Frankfurt stock exchange under the symbol 77I.

The Company has issued two thousand five hundred (2,500) Options to its CFO, Maria Hussaini priced at Friday's close on the CSE at $1.18 per Option for a period of two years.

On behalf of the Board of Directors

Jim Pakulis
Chief Executive Officer
Telephone: (833) 882-6674
www.Booshfood.com

Investor Relations
Contact - Edge Communications Group
Email: invest@booshfood.com
Telephone: (236) 237-1315

About Boosh Plant-Based Brands Inc.:

Boosh Plant-Based Brands Inc., through its wholly owned subsidiary, Boosh Food (www.booshfood.com), is the gateway to experiencing high quality, non-GMO, gluten free, 100% plant-based nutritional comfort foods for the whole family. We currently offer six frozen meals which are sold throughout Canada, and now we're expanding our meals to include three refrigerated products. Boosh, good for you and good for planet earth.

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Forward-looking statements in this news release include, but are not limited to, the Company's proposed use of the proceeds of its initial public offering. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/96285

News Provided by Newsfile via QuoteMedia

boosh food

Boosh Plant-Based Brands

Overview

Analysts project the plant-based meat market has the potential to grow by US$7.21 billion by 2025, with the market’s growth potential to accelerate at a CAGR of 25.14 percent. Consumers and national governing bodies have seen the appeal of more sustainable, plant-based meat alternatives as a long-term food production solution. Put in your source for the above stats

Canada, a global leader in plant protein, has invested over C$950 million in its SuperCluster initiative, with Protein Industries Canada standing as one of five sector recipients of that investment. With rapid popularity in plant-based food alternatives, investors could see exceptional early economic upside in these emerging markets across North America and the rest of the world.

Boosh Plant-Based Brands (CSE:VEGI, OTCQB:VGGIF, FSE: 77I) is a plant-based ready-to-eat food company that distributes and sells plant-based fresh-frozen meals to grocery outlets and independent grocery stores throughout Canada. Founded in 2017 in Vancouver, British Columbia, the company aims to become a leader in delivering plant-based meals, which are sustainably packaged, convenient and tasty for complete customer satisfaction.

Boosh offers an award-winning product line featuring six fresh-frozen “Heat’n Eat” meals, including entrees for one, two and “Booch Pouches,” which are easy-warmed and hearty stews and sauces.

Boosh also provides a fuller range of competitive perks compared to other plant-based competitors. All Boosh meals are 100 percent plant-based, gluten-free, dairy-free and non-GMO. Likewise, the Canadian-based company offers complete composed dishes and two different meal sizes to satisfy individual and family dining wants.

The company has a highly strategic branding supply alliance with Beyond Meat®, one of the leading plant-based meat companies on the market. Numerous benefits have developed from this relationship including utilizing Beyond Meat® in two of Boosh’s dishs, as well as allowing Boosh to market both companies on Boosh packages, which significantly expands brand awareness for both notable companies.

In late 2020, UNFI, one of the largest natural food distributors in North America, began expanding Boosh distribution throughout Canada to over 300 locations and growing. Consumers can find Boosh meals in their local grocery and big box stores like Whole Foods Market, Metro, IGA, Safeway, SPUD.ca and more. With a strong in-store and online presence, Boosh gains exposure across multiple demographics at competitive price points.

The next steps for the company include the exciting launch of Boosh Pouches across grocery outlets in the Summer of 2021, which would introduce new offerings like Sloppy Joes, Mushroom Gravy and Chili. Also, Boosh intends to prepare for its expansion into US markets and roll out a more comprehensive commercial strategy targeting lifestyle channels in the Fall.

Boosh entered into an Asset Purchase Agreement with Saltspring Harvest to acquire the assets comprising Saltspring Harvest’s business. Founded in 2016 by Chef Zoe Currelly, Saltspring Harvest was formed to prove a plant-basprotein-richrich alternatives to meat and dairy focused pâtés and spreads.

With its established 8,500 square foot multi-use facility, the company expects to create extensive promotional content and educational material on the benefits of plant-based lifestyles, which will aid its introduction to new markets.

The Boosh ecosystem is a highly curated chain containing avenues of sourcing, product development, creative direction, distribution and retail store commercialization. With leading executives and industry greats like Boosh’s president, director and founder, Connie Marples, the company is primed for exceptional growth potential and economic success across its expansion plans.

Company Highlights

  • Boosh Plant-Based Brands Inc. is an emerging plant-based comfort food company. It offers accessible, convenient and delicious “Heat’n Eat” fresh-frozen meals to a growing audience and plant-based meat market.
  • Boosh offers an award-winning product line featuring six delicious meals, including Boosh Bowls for One, Boosh Bowls for Two and Boosh Pouches, which will be introduced in Summer 2021.
  • All Boosh meals are 100% plant-based, non-GMO, gluten-free, dairy-free and offer sustainable packaging for its consumers.
  • The company has established itself as a major plant-based competitor on the market with its strategic branding and supply alliance with Beyond Meat
  • Boosh packages are available across over 300 grocery stores Canada-wide through UNFI
  • The next steps for the company include expansion into US markets and creating a more comprehensive commercial strategy to aid its introduction into new markets.
  • Boosh’s entire line of frozen ‘Heat n Eat’ bowls and entrees are now available at all Whole Foods Market locations across Canada.
  • Boosh completed its acquisition of Pulse Kitchen Specialty Foods Ltd.
  • Boosh acquired Beanfields, a company that produces and sells a healthy, gluten-free, non-GMO, vegan, top eight allergen-free flavored bean-based chip.

Key Products

Boosh Bowls

Its “Boosh Bowls for One,” offers a delicious range of meals across a wide set of cuisines like Veggie Bolognese, Mac & Cheeze & Peas, Coconut Curry Cauli, Mexican Fiesta. Additionally, its line of entrees for two offer bigger portions of crowd favorites like Rustic Veggie Pot Pit and award winning Hearty Sheperd’s Pie.

These 100 percent plant-based products contain no dairy, gluten, artificial colors and flavors and are non-GMO. Aimed to attract a wide audience of potential consumers, Boosh Bowls offer competitive pricing, sustainable and fully recyclable packaging and an exceptional plant-based alternative to crowd-favorites.

Boosh Pouches

Boosh’s newest plant-based offering is its Boosh Pouches which are a uniquely delicious line of three “Heat’n Eat” dishes, which include Chili, Mushroom Good Gravy and Sloppy Joe. The company is to begin production on July 30th, 2021 and the products will be distributed in Canada through UNFI.

Management Team

Connie Marples - Founder, Director, CEO & President

Connie Marples is a seasoned executive and entrepreneur with an emphasis on the food and beverage industry. She has held several senior management positions in sales, promotions, marketing and fine dining. In 2003, Marples opened Vintropolis, a Vancouver-based wine bar and bistro/VQA Wine Store and in 2005 Vintropolis received the coveted position of being on the list of Condé Nast Traveller’s Best New Restaurants in the World. She also launched Okanagan Experience, an Entertainment style fundraising coupon book in Kelowna which was later sold to “Entertainment Book”.

As a sales representative, Marples helped launch New York Seltzer, oversaw corporate travel accounts such as the Vancouver Canucks, as well as managed grocery vendor programs and promotional departments at numerous large grocery retailers and radio stations. In the fall of 2020, She won the 2020 BC Food & Beverage Rising Star Award for her development and expansion of Boosh Food. She has expanded Boosh Food into a nationally recognized plant-food brand in Canada where Boosh can be found in over 150 major food retail stores and independent grocers.

Ali Samei - VP Operations / Consultant

Jim Pakulis has over three decades of experience working with public and private entrepreneurial companies in a variety of emerging sectors. He is the former founder, CEO and chairman of TransCanna Holdings Inc., which through his initiative and execution acquired one of the largest vertically integrated cannabis-focused facilities in California. Pakulis has been in senior management positions for numerous publicly traded entities including CEO and chairman of General Cannabis, Inc. which from 2010 to 2012 wholly-owned Weedmaps. He oversaw the growth of General Cannabis from zero to over CAD$16-million in annual revenue.

Maria Hussaini - CPA, Director & CFO

Maria is a Chartered Professional Accountant with sound financial reporting, assurance and tax experience obtained from various roles in public accounting firms. In addition to being CFO of Boosh, she is a financial reporting manager at an accounting advisory practice where she works closely with various publicly traded companies in several industries.

Dave Richardson - Special Advisor

Mr. Richardson has an extensive background assisting emerging growth companies in numerous industries including the plant-based food sector. Mr. Richardson has experience as an investor, executive and founder of multiple technology companies. He is a proponent and defender for sustainability as well as the environment and is an Advisory Board member to several innovative green technology companies, as well as serving as a Director for GreenPower Motor Company.

The Impact of Inaction - New Publication Reveals Not All of Canada is on Track to Meet Global Hepatitis C Elimination Goal

  • Timing of elimination of the hepatitis C virus (HCV) in Canada's provinces indicates 70% of provinces could reach the World Health Organization's (WHO) HCV elimination target of 2030, however three of Canada's provinces — two of them the most populous in the country — are off track to achieve this hepatitis C elimination goal. 1
  • Timely elimination would save 170 lives and $122.6 million in direct medical costs in these three provinces by 2030. 1
  • The Progress Report developed by Action Hepatitis Canada outlines key metrics on which to evaluate HCV elimination progress in Canada , specific to each province. 2
  • In Canada , there are five priority populations and one age-cohort that carry the largest burden of HCV and are recognized as being affected the most by the virus.

ABBVie (NYSE: ABBV) supports a wide range of efforts to help elevate and prioritize hepatitis C virus (HCV) elimination. With a recent publication indicating 70% of Canada's provinces are on track to reach HCV elimination by the World Health Organization's (WHO) initial proposed target of 2030 1 it is important to turn our attention on those affected by the virus and acknowledge that infection with chronic HCV is a global public health concern.

The Impact of Inaction: Timing of Hepatitis C Elimination in Canada. (CNW Group/AbbVie Canada)

In 2016, Canada was one of the 194 countries that committed to support the World Health Organization's (WHO) goal of eliminating viral hepatitis as a public health threat by 2030. With the remarkable progress in HCV therapy, offering the ability to cure patients, this goal seemed possible.

"With the decline in treatment across Canada , it is particularly critical we continue to monitor treatment levels to assess Canada's progress to HCV elimination," said Jordan J Feld, MD MPH, Interim Director, Toronto Centre for Liver Disease, University Health Network, University of Toronto . "We need to continue to pursue novel approaches to case finding and linkage to care, as well as work closely with identified priority populations to ensure that they are able to seek prevention and treatment services without facing stigma and other barriers in the health care system. At the policy level, we need to improve our data sharing abilities across the country to ensure we can track our progress toward elimination."

Populations Most Affected by HCV in Canada 3

  • Indigenous people
  • People with experience in the prison system
  • People born between 1945 and 1975
  • Immigrants and newcomers
  • Gay, bisexual, men who have sex with men (gbMSM)
  • People who inject or use drugs

" Canada has made great strides toward the elimination of hepatitis C. However, there is a lot more work to be done, and the tactics that got us to this point will not necessarily get us to elimination," said Jennifer van Gennip , Executive Director, Action Hepatitis Canada. "Our mandate is to hold the federal and provincial governments accountable to provide the policies and resourced plans to achieve our goal, with focused efforts on priority populations within Canada ."

A look at national treatment data from January 2019 to November 2020 4 confirmed the decreasing trend in treatment levels nationally - a year-over-year decline of 31% in total treatment levels between 2019 and 2020. The report notes that this drop could be due to the disruptions to the healthcare system caused by the COVID-19 pandemic but could also reflect the saturation of treatment among those already linked to care and the difficulties with finding and engaging with individuals and populations not well served by our various healthcare systems. 1

"Everyone has a part to play in eliminating viral hepatitis as it will take more than medicine to achieve this goal," said Tracey Ramsay , Vice-president and General Manager, AbbVie Canada. "AbbVie is committed to partnering with stakeholders to implement sustainable solutions that allow more patients to be screened, linked to care, and treated in a timely manner, especially for those vulnerable patient populations that have lost access to our healthcare system as a result of the pandemic."

Given the available evidence, Canada's momentum towards timely HCV elimination may be jeopardized if diagnosis and treatment are not maintained at appropriate levels. Improved HCV surveillance to build frameworks and innovative approaches to prevention, testing, linkage to care and treatment to achieve this goal is required.

About Hepatitis C

An estimated 250,000 people in Canada are living with chronic hepatitis C but as many as 44% are not aware that they have the disease. 5 Left undiagnosed and untreated, chronic hepatitis C can lead to cirrhosis, liver cancer or liver failure. Currently, hepatitis C is the leading indication for liver transplant in Canada . 6 AbbVie supports a range of efforts to help elevate and prioritize HCV elimination because we know achieving the shared goal of elimination by 2030 will take more than medicine. It will take transparent and collaborative partnerships with all stakeholders – industry, healthcare providers, healthcare systems, patient groups and their support networks. Joint efforts and maximizing the time we have left will enable us to reach this goal.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.ca . Follow AbbVie Canada on Twitter , Instagram and LinkedIn.


1 Timing of elimination of hepatitis C virus in Canada's provinces. https://canlivj.utpjournals.press/doi/full/10.3138/canlivj-2022-0003 . Accessed November 2022.


2 Action Hepatitis Canada. Progress Toward Viral Hepatitis Elimination in Canada. 2021 Report. https://www.actionhepatitiscanada.ca/uploads/8/3/3/9/83398604/ahc_progress_report_2021.pdf . Accessed November 2022.


3 Action Hepatitis Canada. Priority Populations. https://www.actionhepatitiscanada.ca/priority-populations.html . Accessed November 2022.


4 IQVIA GPM National Audit for HCV/Direct Acting Antivirals Market, January 2019–November 2020.


5 Canadian Liver Foundation. https://www.liver.ca/hepatitis-c-warning/ . Accessed November 2022.


6 Canadian Liver Foundation. https://www.liver.ca/how-you-help/advocate/ . Accessed November 2022.

AbbVie logo (CNW Group/AbbVie Canada)

SOURCE AbbVie Canada

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2022/24/c4530.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

AMGEN ANNOUNCES WEBCAST OF 2022 EVERCORE ISI HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 11:20 a.m. ET on Tuesday, November 29, 2022 . David M. Reese M.D., executive vice president of Research and Development at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals

Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") announces that, subsequent to the LOI Sirona and Wanbang Biopharmaceuticals (" Wanbang ") have signed an expanded, international partnership agreement to collaborate on licencing Sirona's SGLT2 inhibitor, TFC-039, as a pharmaceutical treatment in both animal and human health. The agreement adds human health to the partnership as a result of new licencing opportunities currently in due diligence.

Wanbang (a wholly owned subsidiary of Shanghai Fosun Pharmaceutical) and Sirona initially signed a licensing agreement for TFC-039, whereby Wanbang obtained the rights to develop the compound as a diabetes treatment in China and Sirona retained the global rights. Sirona has since been in discussions with animal health companies to advance TFC-039 as a treatment for diabetes and chronic kidney disease in companion animals. SGLT2 inhibitors provide an opportunity to treat inflicted animals with an oral medication as opposed to the traditional method of daily insulin injections. More recently, Sirona has entered into due diligence with a large pharmaceutical company with a regional interest in developing the compound for human diabetes.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AbbVie to Present at the Evercore ISI HealthCONx Conference

ABBVie (NYSE: ABBV) will participate in the 5 th Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, November 29, 2022 . Rob Michael vice chairman and president, Jeffrey R. Stewart executive vice president, commercial operations, Scott Reents senior vice president and chief financial officer, and Tom Hudson senior vice president, R&D and chief scientific officer, will present at 9:55 a.m. Central time .

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be available later that day.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AbbVie Announces European Commission Approval of SKYRIZI® for the Treatment of Moderate to Severe Active Crohn's Disease

A significantly higher proportion of patients on SKYRIZI achieved clinical remission, endoscopic response, mucosal healing and endoscopic remission at week 12 in induction studies compared to placebo 1 2 3 - A significantly higher proportion of patients achieved clinical remission and endoscopic response at week 52 with SKYRIZI maintenance 1, 2, 3 - Crohn's disease is a chronic, systemic inflammatory disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea, abdominal pain and can require urgent medical care 4, 5 ,6

NORTH CHICAGO, Ill. , Nov. 23, 2022 /PRNewswire/ -- ABBVie (NYSE: ABBV) announced the European Commission (EC) approved SKYRIZI ® (risankizumab, 600 mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) as the first specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy. 1,2,3

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting

- Nearly 65 abstracts, including 15 oral presentations on 7 investigational and approved medicines across 8 cancer types, to be presented at the American Society of Hemaotology (ASH) annual congress

ABBVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American Society of Hematology (ASH) annual meeting ( December 10-13 ) in New Orleans, Louisiana .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×